• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NLRC4、ASC 和 Caspase-1 是乳腺癌细胞中由 P2YR 激活介导的炎症小体成分。

NLRC4, ASC and Caspase-1 Are Inflammasome Components that Are Mediated by P2YR Activation in Breast Cancer Cells.

机构信息

Department of Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, 52727 Jinju, Korea.

出版信息

Int J Mol Sci. 2020 May 8;21(9):3337. doi: 10.3390/ijms21093337.

DOI:10.3390/ijms21093337
PMID:32397236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7246622/
Abstract

The inflammasomes are reported to be associated with tumor progression. In our previous study, we determined that extracellular ATP enhances invasion and tumor growth by inducing inflammasome activation in a P2Y purinergic receptor 2 (P2YR)-dependent manner. However, it is not clear which inflammasome among the diverse complexes is associated with P2YR activation in breast cancer. Thus, in this study, we determined which inflammasome components are regulated by P2YR activation and are involved in tumor progression in breast cancer cells and radiotherapy-resistant (RT-R)-breast cancer cells. First, we found that NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3); NLR family caspase activation and recruitment domain (CARD) containing 4 (NLRC4); apoptosis-associated speck-like protein containing a CARD complex (ASC); and caspase-1 mRNA levels were upregulated in RT-R-MDA-MB-231 cells compared to MDA-MB-231 cells, whereas tumor necrosis factor-α (TNF-α) or ATP treatment induced NLRC4, ASC, and caspase-1 but not NLRP3 protein levels. Moreover, TNF-α or ATP increased protein levels of NLRC4, ASC, and caspase-1 in a P2YR-dependent manner in MDA-MB-231 and RT-R-MDA-MB-231 cells. In addition, P2YR activation by ATP induced the secretion of IL-1β and VEGF-A, as well as invasion, in MDA-MB-231 and RT-R-MDA-MB-231 cells, which was inhibited by NLRC4, ASC, and caspase-1 small interfering RNA (siRNA). Taken together, this report suggests that P2YR activation by ATP induces tumor invasion and angiogenesis through inflammasome activation, specifically by regulating the inflammasome components NLRC4, ASC, and caspase-1.

摘要

炎性小体被报道与肿瘤进展有关。在我们之前的研究中,我们确定细胞外 ATP 通过诱导 P2Y 嘌呤能受体 2 (P2YR) 依赖性的炎性小体激活,增强侵袭和肿瘤生长。然而,在乳腺癌中,哪种炎性小体与 P2YR 激活有关尚不清楚。因此,在这项研究中,我们确定了哪种炎性小体成分受 P2YR 激活调节,并参与乳腺癌细胞和放射抵抗 (RT-R)-乳腺癌细胞的肿瘤进展。首先,我们发现 NOD、LRR 和吡喃结构域蛋白 3 (NLRP3);含 N 端 caspase 募集结构域 (CARD) 的 NLR 家族蛋白 4 (NLRC4);凋亡相关斑点样蛋白含有 CARD 结构域 (ASC);和 caspase-1mRNA 水平在 RT-R-MDA-MB-231 细胞中上调,而 TNF-α 或 ATP 处理诱导 NLRC4、ASC 和 caspase-1,但不诱导 NLRP3 蛋白水平。此外,TNF-α 或 ATP 以 P2YR 依赖的方式增加 MDA-MB-231 和 RT-R-MDA-MB-231 细胞中 NLRC4、ASC 和 caspase-1 的蛋白水平。此外,ATP 通过 P2YR 激活诱导 MDA-MB-231 和 RT-R-MDA-MB-231 细胞中 IL-1β 和 VEGF-A 的分泌以及侵袭,这被 NLRC4、ASC 和 caspase-1 小干扰 RNA (siRNA) 抑制。总之,本报告表明,ATP 通过 P2YR 激活诱导肿瘤侵袭和血管生成通过炎性小体激活,特别是通过调节炎性小体成分 NLRC4、ASC 和 caspase-1。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/96168302d535/ijms-21-03337-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/326a4e84b71b/ijms-21-03337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/8d85fcb53ba9/ijms-21-03337-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/709195d54b4f/ijms-21-03337-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/4193f5e9a5ca/ijms-21-03337-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/96168302d535/ijms-21-03337-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/326a4e84b71b/ijms-21-03337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/8d85fcb53ba9/ijms-21-03337-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/709195d54b4f/ijms-21-03337-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/4193f5e9a5ca/ijms-21-03337-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da2/7246622/96168302d535/ijms-21-03337-g005.jpg

相似文献

1
NLRC4, ASC and Caspase-1 Are Inflammasome Components that Are Mediated by P2YR Activation in Breast Cancer Cells.NLRC4、ASC 和 Caspase-1 是乳腺癌细胞中由 P2YR 激活介导的炎症小体成分。
Int J Mol Sci. 2020 May 8;21(9):3337. doi: 10.3390/ijms21093337.
2
Cytokine Secretion and Pyroptosis of Thyroid Follicular Cells Mediated by Enhanced NLRP3, NLRP1, NLRC4, and AIM2 Inflammasomes Are Associated With Autoimmune Thyroiditis.增强的NLRP3、NLRP1、NLRC4和AIM2炎性小体介导的甲状腺滤泡细胞细胞因子分泌和焦亡与自身免疫性甲状腺炎相关。
Front Immunol. 2018 Jun 4;9:1197. doi: 10.3389/fimmu.2018.01197. eCollection 2018.
3
P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer.P2Y2R 介导体细胞焦亡激活参与乳腺癌细胞的肿瘤进展和放疗抵抗型乳腺癌的发生。
Int J Oncol. 2018 Nov;53(5):1953-1966. doi: 10.3892/ijo.2018.4552. Epub 2018 Sep 4.
4
The CARD plays a critical role in ASC foci formation and inflammasome signalling.CARD 在 ASC 焦点形成和炎症小体信号转导中发挥关键作用。
Biochem J. 2013 Feb 1;449(3):613-21. doi: 10.1042/BJ20121198.
5
Tryptanthrin suppresses multiple inflammasome activation to regulate NASH progression by targeting ASC protein.色氨酸酐通过靶向 ASC 蛋白抑制多种炎症小体激活来调节 NASH 进展。
Phytomedicine. 2024 Aug;131:155758. doi: 10.1016/j.phymed.2024.155758. Epub 2024 May 28.
6
NLRP3 regulates a non-canonical platform for caspase-8 activation during epithelial cell apoptosis.NLRP3在上皮细胞凋亡过程中调节半胱天冬酶-8激活的非经典平台。
Cell Death Differ. 2016 Aug;23(8):1331-46. doi: 10.1038/cdd.2016.14. Epub 2016 Feb 19.
7
AIM2 and NLRC4-driven inflammasome activation in adult-onset Still's disease and the preliminary therapeutic effect exploration of carboxyamidotriazole.AIM2 和 NLRC4 驱动的炎症小体激活与成人Still 病,以及羧甲脒三唑的初步治疗效果探索。
Clin Rheumatol. 2023 Jun;42(6):1635-1643. doi: 10.1007/s10067-022-06443-1. Epub 2022 Nov 24.
8
Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation.NLRP3和AIM2炎性小体激活需要核因子E2相关因子2(Nrf2)。
J Biol Chem. 2014 Jun 13;289(24):17020-9. doi: 10.1074/jbc.M114.563114. Epub 2014 May 5.
9
Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC.源自ASC的设计肽对NLRP3炎性小体的选择性抑制作用
FASEB J. 2020 Aug;34(8):11068-11086. doi: 10.1096/fj.201902938RR. Epub 2020 Jul 10.
10
P2Y Receptor Induces Infection Control in a Mechanism Dependent on Caspase-1 Activation and IL-1 Secretion.P2Y 受体通过依赖半胱天冬酶-1 激活和白细胞介素-1 分泌的机制诱导感染控制。
Mediators Inflamm. 2020 Oct 1;2020:2545682. doi: 10.1155/2020/2545682. eCollection 2020.

引用本文的文献

1
NLRC4, inflammation and colorectal cancer (Review).NLRC4、炎症与结直肠癌(综述)。
Int J Oncol. 2024 Oct;65(4). doi: 10.3892/ijo.2024.5687. Epub 2024 Sep 6.
2
Immunohistochemical Expression of Caspase1 and Epidermal Growth Factor Receptor in Invasive Breast Carcinoma and Their Biological and Prognostic Associations.免疫组织化学检测 Caspase1 和表皮生长因子受体在浸润性乳腺癌中的表达及其与生物学和预后的关系。
Asian Pac J Cancer Prev. 2024 Jul 1;25(7):2529-2537. doi: 10.31557/APJCP.2024.25.7.2529.
3
Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics.

本文引用的文献

1
Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells.肿瘤微环境中 NLRP3 炎性小体的抑制导致癌细胞转移潜能的抑制。
Sci Rep. 2019 Aug 22;9(1):12277. doi: 10.1038/s41598-019-48794-x.
2
Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy.炎症小体:癌症免疫学和免疫治疗中的新兴核心参与者。
Front Immunol. 2018 Dec 20;9:3028. doi: 10.3389/fimmu.2018.03028. eCollection 2018.
3
Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells.
对嘌呤能P2受体在疾病中的潜在作用的全面见解:涉及的信号通路及潜在治疗方法。
J Adv Res. 2025 Mar;69:427-448. doi: 10.1016/j.jare.2024.03.027. Epub 2024 Mar 31.
4
Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).颠覆乳腺癌治疗模式:调控细胞死亡相关机制与药物的应用(综述)。
Int J Oncol. 2024 May;64(5). doi: 10.3892/ijo.2024.5634. Epub 2024 Mar 8.
5
A potential immunotherapy target for breast cancer: parenchymal and immune-stromal expression of the NLRP3 inflammasome pathway.乳腺癌的潜在免疫治疗靶点:NLRP3 炎性小体通路的实质和免疫基质表达。
BMC Cancer. 2023 Nov 29;23(1):1163. doi: 10.1186/s12885-023-11609-4.
6
Inflammasome: structure, biological functions, and therapeutic targets.炎性小体:结构、生物学功能及治疗靶点
MedComm (2020). 2023 Oct 9;4(5):e391. doi: 10.1002/mco2.391. eCollection 2023 Oct.
7
Divergent functions of NLRP3 inflammasomes in cancer: a review.NLRP3 炎性体在癌症中的不同功能:综述。
Cell Commun Signal. 2023 Sep 15;21(1):232. doi: 10.1186/s12964-023-01235-9.
8
Molecular mechanisms of pyroptosis and its role in anti-tumor immunity.细胞焦亡的分子机制及其在抗肿瘤免疫中的作用。
Int J Biol Sci. 2023 Aug 6;19(13):4166-4180. doi: 10.7150/ijbs.86855. eCollection 2023.
9
The Progress of Platelets in Breast Cancer.血小板在乳腺癌中的研究进展
Cancer Manag Res. 2023 Aug 11;15:811-821. doi: 10.2147/CMAR.S418574. eCollection 2023.
10
Inflammasome-Independent Roles of NLR and ALR Family Members.NLR 和 ALR 家族成员的炎性小体非依赖性作用。
Methods Mol Biol. 2023;2696:29-45. doi: 10.1007/978-1-0716-3350-2_2.
耐辐射乳腺癌细胞由于癌症干细胞的存在而表现出对化疗的更高抗性和增强的侵袭特性。
Oncol Rep. 2018 Dec;40(6):3752-3762. doi: 10.3892/or.2018.6714. Epub 2018 Sep 18.
4
P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer.P2Y2R 介导体细胞焦亡激活参与乳腺癌细胞的肿瘤进展和放疗抵抗型乳腺癌的发生。
Int J Oncol. 2018 Nov;53(5):1953-1966. doi: 10.3892/ijo.2018.4552. Epub 2018 Sep 4.
5
IL-1 and IL-1 regulatory pathways in cancer progression and therapy.IL-1 和 IL-1 调节通路在癌症进展和治疗中的作用。
Immunol Rev. 2018 Jan;281(1):57-61. doi: 10.1111/imr.12614.
6
NLRP1 Overexpression Is Correlated with the Tumorigenesis and Proliferation of Human Breast Tumor.NLRP1 过表达与人类乳腺癌的肿瘤发生和增殖相关。
Biomed Res Int. 2017;2017:4938473. doi: 10.1155/2017/4938473. Epub 2017 Oct 29.
7
Polymeric Nanoparticles Induce NLRP3 Inflammasome Activation and Promote Breast Cancer Metastasis.聚合物纳米颗粒诱导 NLRP3 炎性小体激活并促进乳腺癌转移。
Macromol Biosci. 2017 Dec;17(12). doi: 10.1002/mabi.201700273. Epub 2017 Nov 13.
8
The P2X7 Receptor in Infection and Inflammation.P2X7 受体在感染和炎症中的作用。
Immunity. 2017 Jul 18;47(1):15-31. doi: 10.1016/j.immuni.2017.06.020.
9
Targeting Inflammation in Cancer Prevention and Therapy.癌症预防与治疗中的炎症靶向作用
Cancer Prev Res (Phila). 2016 Dec;9(12):895-905. doi: 10.1158/1940-6207.CAPR-16-0209. Epub 2016 Nov 10.
10
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression.肥胖相关 NLRC4 炎性小体激活促进乳腺癌进展。
Nat Commun. 2016 Oct 6;7:13007. doi: 10.1038/ncomms13007.